Need help finding what you are looking for?
Contact Us
PUBLISHER: IMARC | PRODUCT CODE: 1541322
PUBLISHER: IMARC | PRODUCT CODE: 1541322
Osteoporosis Drugs Market Report by Product Type, Route of Administration, and Region 2024-2032
PUBLISHED:
PAGES: 141 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
The global osteoporosis drugs market size reached US$ 16.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 24.3 Billion by 2032, exhibiting a growth rate (CAGR) of 4.2% during 2024-2032.
Osteoporosis is a disease that causes deterioration of bone tissues and strength. It is diagnosed by performing different scans, such as X-ray, computed tomography (CT) and magnetic resonance imaging (MRI). Various drugs are currently available in different formulations, ranging from regular tablets to intravenous (IV) infusions, for alleviating the symptoms of osteoporosis. These drugs help restore the balance of resorption and formation, repair microscopic defects in bones, reduce the risk of fractures and improve the overall muscle strength of the patients.
The growing prevalence of osteoporosis on account of sedentary lifestyles, excessive consumption of alcohol, and rising utilization of tobacco represent the key factors bolstering the growth of the market. The increasing number of individuals who have celiac disease, kidney or liver disease, cancer, lupus, multiple myeloma and rheumatoid arthritis is further accelerating the market growth. Moreover, bone mass loss increases with age, which raises the risk of developing osteoporosis among older people. Consequently, the rising geriatric population is positively influencing the demand for osteoporosis drugs worldwide. Furthermore, several governing authorities are developing novel therapeutics, which is contributing to the market growth. For instance, the US Food and Drug Administration (FDA) has approved novel osteoporosis drugs for postmenopausal women who are at a high risk of fractures or are intolerant to other osteoporosis therapies. Besides this, a wide range of drugs in late-stage clinical trials is anticipated to propel the market growth in the coming years.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global osteoporosis drugs market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product type and route of administration.
Breakup by Product Type:
Bisphosphonates
Calcitonin
Rank Ligand Inhibitor
Parathyroid Hormone Therapy (PTH)
Selective Estrogen Receptor Modulators (SERMs)
Sclerostin Inhibitor
Others
Breakup by Route of Administration:
Oral
Injectable
Others
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Amgen Inc., Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Merck & Co. Inc., Novartis AG, Pfizer Inc., Radius Health Inc., Teva Pharmaceutical Industries Ltd. and UCB S.A.
Key Questions Answered in This Report
- 1. How big is the global osteoporosis drugs market?
- 2. What is the expected growth rate of the global osteoporosis drugs market during 2024-2032?
- 3. What are the key factors driving the global osteoporosis drugs market?
- 4. What has been the impact of COVID-19 on the global osteoporosis drugs market?
- 5. What is the breakup of the global osteoporosis drugs market based on the product type?
- 6. What is the breakup of the global osteoporosis drugs market based on the route of administration?
- 7. What are the key regions in the global osteoporosis drugs market?
- 8. Who are the key players/companies in the global osteoporosis drugs market?
Product Code: SR112024A3104
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Osteoporosis Drugs Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Product Type
- 6.1 Bisphosphonates
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Calcitonin
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Rank Ligand Inhibitor
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 6.4 Parathyroid Hormone Therapy (PTH)
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
- 6.5 Selective Estrogen Receptor Modulators (SERMs)
- 6.5.1 Market Trends
- 6.5.2 Market Forecast
- 6.6 Sclerostin Inhibitor
- 6.6.1 Market Trends
- 6.6.2 Market Forecast
- 6.7 Others
- 6.7.1 Market Trends
- 6.7.2 Market Forecast
7 Market Breakup by Route of Administration
- 7.1 Oral
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Injectable
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Others
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
8 Market Breakup by Region
- 8.1 North America
- 8.1.1 United States
- 8.1.1.1 Market Trends
- 8.1.1.2 Market Forecast
- 8.1.2 Canada
- 8.1.2.1 Market Trends
- 8.1.2.2 Market Forecast
- 8.1.1 United States
- 8.2 Asia-Pacific
- 8.2.1 China
- 8.2.1.1 Market Trends
- 8.2.1.2 Market Forecast
- 8.2.2 Japan
- 8.2.2.1 Market Trends
- 8.2.2.2 Market Forecast
- 8.2.3 India
- 8.2.3.1 Market Trends
- 8.2.3.2 Market Forecast
- 8.2.4 South Korea
- 8.2.4.1 Market Trends
- 8.2.4.2 Market Forecast
- 8.2.5 Australia
- 8.2.5.1 Market Trends
- 8.2.5.2 Market Forecast
- 8.2.6 Indonesia
- 8.2.6.1 Market Trends
- 8.2.6.2 Market Forecast
- 8.2.7 Others
- 8.2.7.1 Market Trends
- 8.2.7.2 Market Forecast
- 8.2.1 China
- 8.3 Europe
- 8.3.1 Germany
- 8.3.1.1 Market Trends
- 8.3.1.2 Market Forecast
- 8.3.2 France
- 8.3.2.1 Market Trends
- 8.3.2.2 Market Forecast
- 8.3.3 United Kingdom
- 8.3.3.1 Market Trends
- 8.3.3.2 Market Forecast
- 8.3.4 Italy
- 8.3.4.1 Market Trends
- 8.3.4.2 Market Forecast
- 8.3.5 Spain
- 8.3.5.1 Market Trends
- 8.3.5.2 Market Forecast
- 8.3.6 Russia
- 8.3.6.1 Market Trends
- 8.3.6.2 Market Forecast
- 8.3.7 Others
- 8.3.7.1 Market Trends
- 8.3.7.2 Market Forecast
- 8.3.1 Germany
- 8.4 Latin America
- 8.4.1 Brazil
- 8.4.1.1 Market Trends
- 8.4.1.2 Market Forecast
- 8.4.2 Mexico
- 8.4.2.1 Market Trends
- 8.4.2.2 Market Forecast
- 8.4.3 Others
- 8.4.3.1 Market Trends
- 8.4.3.2 Market Forecast
- 8.4.1 Brazil
- 8.5 Middle East and Africa
- 8.5.1 Market Trends
- 8.5.2 Market Breakup by Country
- 8.5.3 Market Forecast
9 SWOT Analysis
- 9.1 Overview
- 9.2 Strengths
- 9.3 Weaknesses
- 9.4 Opportunities
- 9.5 Threats
10 Value Chain Analysis
11 Porters Five Forces Analysis
- 11.1 Overview
- 11.2 Bargaining Power of Buyers
- 11.3 Bargaining Power of Suppliers
- 11.4 Degree of Competition
- 11.5 Threat of New Entrants
- 11.6 Threat of Substitutes
12 Price Analysis
13 Competitive Landscape
- 13.1 Market Structure
- 13.2 Key Players
- 13.3 Profiles of Key Players
- 13.3.1 Amgen Inc.
- 13.3.1.1 Company Overview
- 13.3.1.2 Product Portfolio
- 13.3.1.3 Financials
- 13.3.1.4 SWOT Analysis
- 13.3.2 Eli Lilly and Company
- 13.3.2.1 Company Overview
- 13.3.2.2 Product Portfolio
- 13.3.2.3 Financials
- 13.3.2.4 SWOT Analysis
- 13.3.3 F. Hoffmann-La Roche AG
- 13.3.3.1 Company Overview
- 13.3.3.2 Product Portfolio
- 13.3.3.3 SWOT Analysis
- 13.3.4 GlaxoSmithKline Plc
- 13.3.4.1 Company Overview
- 13.3.4.2 Product Portfolio
- 13.3.4.3 Financials
- 13.3.4.4 SWOT Analysis
- 13.3.5 Merck & Co. Inc.
- 13.3.5.1 Company Overview
- 13.3.5.2 Product Portfolio
- 13.3.5.3 Financials
- 13.3.5.4 SWOT Analysis
- 13.3.6 Novartis AG
- 13.3.6.1 Company Overview
- 13.3.6.2 Product Portfolio
- 13.3.6.3 Financials
- 13.3.6.4 SWOT Analysis
- 13.3.7 Pfizer Inc.
- 13.3.7.1 Company Overview
- 13.3.7.2 Product Portfolio
- 13.3.7.3 Financials
- 13.3.7.4 SWOT Analysis
- 13.3.8 Radius Health Inc.
- 13.3.8.1 Company Overview
- 13.3.8.2 Product Portfolio
- 13.3.8.3 Financials
- 13.3.9 Teva Pharmaceutical Industries Ltd.
- 13.3.9.1 Company Overview
- 13.3.9.2 Product Portfolio
- 13.3.9.3 Financials
- 13.3.9.4 SWOT Analysis
- 13.3.10 UCB S.A.
- 13.3.10.1 Company Overview
- 13.3.10.2 Product Portfolio
- 13.3.10.3 Financials
- 13.3.10.4 SWOT Analysis
- 13.3.1 Amgen Inc.
Product Code: SR112024A3104
List of Figures
- Figure 1: Global: Osteoporosis Drugs Market: Major Drivers and Challenges
- Figure 2: Global: Osteoporosis Drugs Market: Sales Value (in Billion US$), 2018-2023
- Figure 3: Global: Osteoporosis Drugs Market: Breakup by Product Type (in %), 2023
- Figure 4: Global: Osteoporosis Drugs Market: Breakup by Route of Administration (in %), 2023
- Figure 5: Global: Osteoporosis Drugs Market: Breakup by Region (in %), 2023
- Figure 6: Global: Osteoporosis Drugs Market Forecast: Sales Value (in Billion US$), 2024-2032
- Figure 7: Global: Osteoporosis Drugs (Bisphosphonates) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 8: Global: Osteoporosis Drugs (Bisphosphonates) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 9: Global: Osteoporosis Drugs (Calcitonin) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 10: Global: Osteoporosis Drugs (Calcitonin) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 11: Global: Osteoporosis Drugs (Rank Ligand Inhibitor) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 12: Global: Osteoporosis Drugs (Rank Ligand Inhibitor) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 13: Global: Osteoporosis Drugs (Parathyroid Hormone Therapy- PTH) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 14: Global: Osteoporosis Drugs (Parathyroid Hormone Therapy- PTH) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 15: Global: Osteoporosis Drugs (Selective Estrogen Receptor Modulators- SERMs) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 16: Global: Osteoporosis Drugs (Selective Estrogen Receptor Modulators- SERMs) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 17: Global: Osteoporosis Drugs (Sclerostin Inhibitor) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 18: Global: Osteoporosis Drugs (Sclerostin Inhibitor) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 19: Global: Osteoporosis Drugs (Others) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 20: Global: Osteoporosis Drugs (Others) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 21: Global: Osteoporosis Drugs (Oral) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 22: Global: Osteoporosis Drugs (Oral) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 23: Global: Osteoporosis Drugs (Injectable) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 24: Global: Osteoporosis Drugs (Injectable) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 25: Global: Osteoporosis Drugs (Others) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 26: Global: Osteoporosis Drugs (Others) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 27: North America: Osteoporosis Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 28: North America: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 29: United States: Osteoporosis Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 30: United States: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 31: Canada: Osteoporosis Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 32: Canada: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 33: Asia-Pacific: Osteoporosis Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 34: Asia-Pacific: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 35: China: Osteoporosis Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 36: China: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 37: Japan: Osteoporosis Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 38: Japan: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 39: India: Osteoporosis Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 40: India: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 41: South Korea: Osteoporosis Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 42: South Korea: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 43: Australia: Osteoporosis Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 44: Australia: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 45: Indonesia: Osteoporosis Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 46: Indonesia: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 47: Others: Osteoporosis Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 48: Others: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 49: Europe: Osteoporosis Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 50: Europe: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 51: Germany: Osteoporosis Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 52: Germany: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 53: France: Osteoporosis Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 54: France: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 55: United Kingdom: Osteoporosis Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 56: United Kingdom: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 57: Italy: Osteoporosis Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 58: Italy: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 59: Spain: Osteoporosis Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 60: Spain: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 61: Russia: Osteoporosis Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 62: Russia: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 63: Others: Osteoporosis Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 64: Others: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 65: Latin America: Osteoporosis Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 66: Latin America: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 67: Brazil: Osteoporosis Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 68: Brazil: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 69: Mexico: Osteoporosis Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 70: Mexico: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 71: Others: Osteoporosis Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 72: Others: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 73: Middle East and Africa: Osteoporosis Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 74: Middle East and Africa: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 75: Middle East and Africa: Osteoporosis Drugs Market: Breakup by Country (in %), 2023
- Figure 76: Global: Osteoporosis Drugs Industry: SWOT Analysis
- Figure 77: Global: Osteoporosis Drugs Industry: Value Chain Analysis
- Figure 78: Global: Osteoporosis Drugs Industry: Porter's Five Forces Analysis
List of Tables
- Table 1: Global: Osteoporosis Drugs Market: Key Industry Highlights, 2023 and 2032
- Table 2: Global: Osteoporosis Drugs Market Forecast: Breakup by Product Type (in Million US$), 2024-2032
- Table 3: Global: Osteoporosis Drugs Market Forecast: Breakup by Route of Administration (in Million US$), 2024-2032
- Table 4: Global: Osteoporosis Drugs Market Forecast: Breakup by Region (in Million US$), 2024-2032
- Table 5: Global: Osteoporosis Drugs Market: Competitive Structure
- Table 6: Global: Osteoporosis Drugs Market: Key Players
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.